Dan Gorenstein

California is making the nation's most ambitious effort yet to cover non-traditional health care services like housing and food for some of the state's sickest and most vulnerable residents.

Medicare's annual open enrollment period began Oct. 15, allowing seniors to choose new plans. New rules this year are supposed to crack down on misleading marketing but buyers should still beware.

About 12 million Americans are known as "dual eligibles" because they need both Medicare and Medicaid. A bipartisan bill offers hope to cut through the tangle of red tape that often ensnares them.

Medicare soon will start something it hasn't done in its 58-year history: Negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

The 3-digit suicide prevention lifeline went live a year ago. More work is needed on the 988 system, but the first year has gone more smoothly than many expected.

Powerful new artificial intelligence tools can perpetuate long-standing racial inequities if they are not designed very carefully. Researchers and regulators are taking note, but perils are vast.

The end-of-life benefit costs billions a year. A new approach aims to eliminate waste and weed out bad actors, while making the care more inviting to those who most need it.

People leaving jail or prison are at extremely high risk of hospitalization and death, and policymakers from deep blue California to solidly red Utah think bringing Medicaid behind bars could help.

She's seen what happens when people don't trust or understand their doctor. Dr. Lisa Fitzpatrick founded 'Grapevine Health' to get solid information out, especially to Black and Latinx patients.

Drugmakers will be required to pay Medicare back for price increases that outpace inflation. The industry is expected to put up a fight over implementation.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

The Inflation Reduction Act gives Medicare historic new powers to limit prescription drug prices. But the pharmaceutical industry is already lobbying to dull their impact.

Independent funds that help people pay for abortions have been flooded with donations since Roe v. Wade was overturned, but demand and costs are also rising as more states enact restrictive bans.

MRIs done early for uncomplicated low back pain and routine vitamin D tests "just to be thorough" are considered "low-value care" and can lead to further testing that can cost patients thousands.

A growing number of private insurance companies are starting to invest in medical respite — a decades-old way of caring for homeless people. Here's what's driving the trend.

Over 9 million Americans have lost both their job and health coverage. To help them, COBRA is an option, but it could cost buyers more than if subsidies were increased for Affordable Care Act plans.

Matching the sickest patients with social workers and medical support doesn't reduce costly hospital readmissions, a study finds. Still, some believe greater social investment could make a difference.